Apotex Health announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals, to integrate Cumberland's U.S. branded businesses into Apotex.
With the completion of the strategic transaction, Apotex adds a portfolio of established branded medicines to its U.S. business, expanding its specialty and hospital-focused presence across key therapeutic areas including acute care, oncology, infectious disease, and gastroenterology.
"This milestone strengthens our ability to support patients and healthcare providers across the United States," said Jeff Watson, President & CEO of Apotex. "We look forward to integrating these important medicines into our portfolio and expanding access to high-quality treatments."
"We are pleased to have completed this strategic transaction with Apotex, which will create more critical mass to better support patient care," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.
The portfolio includes well-established brands, including Kristalose®, Caldolor®, Sancuso®, Vibativ®, Acetadote®, Vaprisol®, and Talicia®, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!